Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Structure-based computational discovery of a novel HDAC2 inhibitor with predicted superior binding and activity; lacks experimental validation in cells or organisms, representing early-stage hypothesis-generating work.
A single-arm, proof-of-concept study in cell lines and one mouse model showing mechanistic restoration of chemosensitivity in a drug-resistant breast cancer line, with clear biological signals but lacking comparative controls and human efficacy data.
This is an early-stage chemical synthesis and in vitro screening study with no animal or clinical data; it raises the question whether these compounds merit further development but does not yet answer whether they are safe or effective in disease.
The American Journal of Science and Medical Research
This is a computational molecular docking study with no experimental validation, comparing phytochemical binding affinity to AChE in silico; it raises mechanistic questions but provides no evidence of biological activity or clinical relevance.
The American Journal of Science and Medical Research
This is an in silico molecular docking study with no experimental validation; it raises mechanistic questions about natural compounds as AChE inhibitors but does not answer them with empirical data.
A review of chemical structures and in vitro enzyme inhibition data supporting triazole compounds as potential AD agents, without clinical trial evidence or in vivo efficacy demonstration.